This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matthews, D. R Articles by Wallace, T. M Search for Related Content Social Bookmarking                   What's this?

Review: Sulphonylureas and the rise and fall of beta-cell function

Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churchill Hospital, Headington, Oxford, OX3 7LJ, UK

Tara M Wallace

david.matthews{at}ocdem.ox.ac.uk

Sulphonylureas are an accepted and widely used treatment for hyperglycaemia in type 2 diabetes. The UK Prospective Diabetes Study (UKPDS) demonstrated that, like other oral agents used in clinical practice, there are early good results which fail over time. Conclusions drawn show that it is in fact a result of progressive loss of beta-cell function. Results from the UKPDS and several other studies reinforce the need for ongoing and tailored treatment to maintain glycaemic control and slow symptom progression. So sulphonylureas improve beta-cell function in those with type 2 diabetes over many years, but their effects are lessened by progressive beta-cell failure. In the enthusiasm for new therapies they should not be neglected as a mainstay of oral treatment early in the course of type 2 diabetes.

Key Words: sulphonylureas • type 2 diabetes • beta-cell • insulin secretion • insulin resistance.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 4, 192-196 (2005)
DOI: 10.1177/14746514050050040301


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?